OPEN LABEL, DOSE ESCALATION STUDY OF SNX-111 ADMINISTERED INTRATHECALLY TO PT

SNX-111 鞘内给予 PT 的开放标签剂量递增研究

• 批准号: 6278178
• 负责人: VALERIE C ANDERSON
• 金额: $ 2.86万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278178
• 关键词: calcium channel blockers; chronic pain; clinical research; clinical trials; drug delivery systems; drug screening /evaluation; human subject; human therapy evaluation; nervous system disorder chemotherapy

SNX-111 is a voltage-sensitive calcium channel blocker that specifically blocks neuronal (N-type) calcium channels. These channels are found in highest density within the substantia gelatinosa of the dorsal horn, where blockade of calcium influx has been shown to produce analgesia. The present study is designed to evaluate the safety and efficacy of low dose, intrathecal SNX-111 in relieving chronic, nonmalignant pain. Drug will be delivered via implanted intrathecal infusion system. Dose will be titrated weekly over 7 weeks until analgesia is achieved or until intolerable side effects occur.

SNX-111是一种电压敏感性钙通道阻滞剂， 阻断神经元（N型）钙通道。 这些通道位于 背角胶状质内密度最高， 钙流入的阻断已显示产生镇痛作用。 的 本研究旨在评估低剂量的安全性和有效性， 鞘内注射SNX-111缓解慢性非恶性疼痛。 药物将 通过植入的鞘内输注系统输送。 剂量将 每周滴定一次，持续7周，直至达到镇痛效果或直至 会出现无法忍受的副作用。